98%
921
2 minutes
20
Background: Evidence on prophylactic venoarterial extracorporeal membrane oxygenation (VA-ECMO) during elective percutaneous coronary intervention (PCI) in patients with complex high-risk coronary artery lesions is limited.
Objectives: The authors aimed to assess the safety and effectiveness of prophylactic VA-ECMO during PCI.
Methods: This single-center, randomized trial enrolled 70 patients with complex high-risk coronary lesions (Synergy Between PCI with Taxus and Cardiac Surgery [SYNTAX] score ≥33) who declined coronary artery bypass grafting. Patients were divided into those who had prophylactic VA-ECMO (n = 34) prior to PCI and controls who did not have prophylactic VA-ECMO (n = 36). Elective PCI was performed, and complications were recorded. Life-threatening complications included: 1) cardiac arrest unresponsive to cardiopulmonary resuscitation; 2) cardiogenic shock; 3) acute left heart failure unresponsive to therapy; and 4) refractory malignant arrhythmias. SYNTAX scores pre- and post-PCI were calculated. The primary endpoints were the rate of complications during PCI and SYNTAX score reduction post-PCI.
Results: Between June 2021 and August 2023, 70 patients (women: 14.3%) underwent PCI. SYNTAX scores in the VA-ECMO and control group were similar (37.8 [34.5-44.0] vs 35.8 [33.2-40.8], P = 0.11). Life-threatening complications were lower in the VA-ECMO group compared to controls (0% vs 19.4%; P = 0.01). Emergency VA-ECMO was required in 19.4% of the control group. The VA-ECMO group showed greater absolute reduction in SYNTAX scores (27.2 [24.5-35.0] vs 22.5 [11.5-32.8], P = 0.04).
Conclusions: In this single-center study of patients undergoing elective PCI of complex high-risk coronary lesions, prophylactic VA-ECMO was associated with lower rates of life-threatening complications and larger reduction in SYNTAX scores. Larger studies are needed to further define optimal management strategies in high-risk complex PCI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398820 | PMC |
http://dx.doi.org/10.1016/j.jacadv.2025.102095 | DOI Listing |
JACC Adv
August 2025
The First School of Clinical Medicine of Lanzhou University, Lanzhou, China; Heart Center, The First Hospital of Lanzhou University, Lanzhou, China; Gansu Province Clinical Research Center for Cardiovascular Diseases, Lanzhou, China. Electronic address:
Background: Evidence on prophylactic venoarterial extracorporeal membrane oxygenation (VA-ECMO) during elective percutaneous coronary intervention (PCI) in patients with complex high-risk coronary artery lesions is limited.
Objectives: The authors aimed to assess the safety and effectiveness of prophylactic VA-ECMO during PCI.
Methods: This single-center, randomized trial enrolled 70 patients with complex high-risk coronary lesions (Synergy Between PCI with Taxus and Cardiac Surgery [SYNTAX] score ≥33) who declined coronary artery bypass grafting.
Perfusion
July 2025
Department of Surgery, Johns Hopkins Medicine, Baltimore, MD, USA.
ObjectivesThe platelet trigger at which to transfuse platelets to prevent bleeding complications in patients supported with extracorporeal membrane oxygenation (ECMO) is unclear. We aimed to elucidate the association between platelet count and bleeding sequelae in this patient population.MethodsWe conducted a single-center retrospective study of all adult patients who received ECMO support from 2017 to 2022.
View Article and Find Full Text PDFPerfusion
July 2025
Adult Intensive Care Unit, Presbyterian Hospital, Albuquerque, NM, USA.
IntroductionBlood Stream Infections (BSI) occur in 3-35% of patients on ECMO (Extracorporeal membrane Oxygenation). With the increased use of ECMO since the COVID-19 pandemic, the magnitude of this problem has increased. There are no clear established practice guidelines for BSI prevention on ECMO.
View Article and Find Full Text PDFJ Infect Dev Ctries
July 2025
Department of Intensive Care Medicine, Army Medical Center of PLA, Chongqing, China.
Introduction: The aim of this study was to summarize the infection situation of patients during extracorporeal membrane oxygenation (ECMO) treatment, and analyze the relevant infectious indexes before and after ECMO treatment; so as to provide clinical evidence for the control of infection after ECMO treatment.
Methodology: A retrospective analysis was conducted from May 2014 to January 2024 on 66 patients treated with ECMO at the Department of Intensive Care Medicine, Daping Hospital, Army Medical University. The patients' general clinical data were collected, focusing on infection types, pathogenic bacteria, anti-infective regimens, infection markers, and coagulation function.
J Infect Chemother
August 2025
Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
Ganciclovir (GCV) plays an important role in preventing cytomegalovirus (CMV) infection after lung transplantation. Because of the large inter-individual and intra-individual variabilities in GCV pharmacokinetics, it has been suggested that individualized dosages based on blood levels are required. However, GCV pharmacokinetics during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is unknown.
View Article and Find Full Text PDF